Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclosporine + prednisolone is a combination of two immunosuppressive agents used primarily for the treatment of immune-mediated diseases, particularly when monotherapy is insufficient or not tolerated. Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by inhibiting the phosphatase activity of calcineurin, thereby reducing the transcription of interleukin-2 and other cytokines essential for T-cell proliferation and function[5][6][8]. Prednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene expression to inhibit pro-inflammatory signals and promote anti-inflammatory effects[10]. The combination has been shown to be effective in conditions such as pemphigus vulgaris, refractory celiac disease, and minimal change nephrotic syndrome where rapid immunosuppression or steroid-sparing effects are desired[1][2][3]. This regimen can induce remission more quickly than corticosteroids alone in some cases and may allow for lower doses of each drug, potentially reducing side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclosporine + prednisolone.